Pivotal Trial Of Carmat’s Total Artificial Heart Delayed
Executive Summary
Carmat suspended the production of its Total Artificial Heart while it strengthens certain manufacturing processes.
You may also be interested in...
Carmat To Launch Total Artificial Heart In Early 2021
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.
Results Recap: Medtronic Highlights Data To Contrast With Recent Meta-Analysis That Sparked Drug-Coated Balloon Scrutiny
This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial-results from MedDeviceTracker, includes medical device trial results announced from Jan. 11 through Jan. 24. This week's list is dominated by results presentations from the Leipzig Interventional Course (LINC) in Leipzig, Germany, including trials of devices from Medtronic, Boston Scientific, Gore, Profusa, InspireMD, and Vessi.
Minute Insight: FDA Approves First Fluorescent Imaging Agent For Ovarian Cancer
On Target Laboratories’ Cytalux (pafolacianine) is now approved for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.